Article
Pharmaceutical Executive
Pharmaceutical Executive
In 1981, pharma was a more innocent industry. It stood on the brink of an AIDS epidemic that science had yet to name or understand. Hazards of generics, product lifecycles, and off-label marketing lay years ahead. There were no embryonic stem cells to fight over--nor euphemisms like "overactive bladder syndrome" and "erectile dysfunction" to ease conversations or kick off ad campaigns. Who knew what awaited us? To remember--and to reflect on what shaped modern pharma--we invite you to page through the most significant events of the past quarter century.
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.